BUSINESS WIRE; Thursday December 11, 8:04 am EST
StatSimple pylori is a self-contained system for the collection, processing and analysis of a whole blood specimen for the detection of antibodies to Helicobacter pylori (H.pylori) bacterium. The specimen is obtained from a finger stick. Results can be read within minutes without instrumentation. The Company believes this assay is ideal for on-site testing, general screening purposes and epidemiological studies, the product is not approved for sale in the US.
Dr. Paul Slowey, Chief Operating Officer and Vice President of Marketing and Sales for SDS stated: "The new product generated enthusiasm and keen interest when it was demonstrated at Medica."
"This test can expedite the detection of the H.pylori infection to allow early treatment. This is important because H.pylori infection has been implicated in a variety of other illnesses such as gastric cancers, heart disease and certain allergies" added Slowey.
The Company expects that StatSimple pylori will be ready for distribution and sale in Europe during the first quarter of 1998.
Saliva Diagnostic Systems, Inc. is a developer and manufacturer of rapid tests for infectious diseases and certain other conditions. The Company is based in Vancouver, Washington with a sales office in London, England. The Company is in the process of developing rapid serum and saliva tests for Hepatitis A and Tuberculosis. The Company's products include a range of rapid tests to detect HIV antibodies that use serum, whole blood or saliva for analysis. The tests, which require only a few simple steps to use, are designed to produce results within minutes without special equipment, training or storage.
This press release contains forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to vary include the ability of the Company to raise additional capital, demand for the Company's products, the ability of the Company to obtain regulatory approvals, success in the Company's technological advances and their implementation, as well as other risk factors listed in the Company's Registration Statement on Form S-3 dated September 26, 1997.
Contact: Saliva Diagnostic Systems, Inc. Tel: 360/696-4800 Fax: 360/254-7942
Copyright (c) 1997/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
971211
BW971206
Copyright © 1997 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .